Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now later-stage tilt small index

Circadian Dysregulation: later-stage trial registry

3 of 11 indexed Circadian Dysregulation trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #1,577 of 28,707 conditions by registered trial count.

11 US clinical trials · 3 currently recruiting · #1,577 of 28,707 conditions by registered trial count

Circadian Dysregulation: 11 US clinical trials tracked, 3 recruiting.

Circadian Dysregulation is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is University of California, Berkeley, running 2 of these trials.

Enrollment posture brief

Registry condition circadian-dysregulation

OPEN 3 | RECR 27% | LATE 1 | EARLY 0 | RANK #1577 | SPON 2

Nearest open-share peer: Atherosclerotic Cardiovascular Disease (27% recruiting · 22 trials)

Acute Pancreatitis81.8%Acute Stroke45.5%Acquired Brain Injury36.4%Circadian Dysregulation (thi…27%Acute Lung Injury9.1%
Open-enrollment share among volume-matched conditions near Circadian Dysregulation

Circadian Dysregulation lists 3 open slots (27% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Circadian Dysregulation on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Circadian Dysregulation is recruiting below its size-band peers.

    3 of 11 indexed trials (27.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Circadian Dysregulation research.

    University of California, Berkeley accounts for 2 of 11 trials (18.2%). 10 distinct sponsors appear on at least one study for this condition label.

  3. Most Circadian Dysregulation trials plan to enrol fewer than 100 people.

    Median target enrolment is 30 among the 11 trials that report a genuine target (sentinel values excluded). 7 of those (63.6%) plan for fewer than 100 participants.

  4. Circadian Dysregulation research is mostly interventional.

    10 interventional and 1 observational studies make up this index (90.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 41

Open and recent trials

11 total, page 1 of 1

RECRUITING NA 178 participants

NIA_Improving Function and Well-being by Improving Patient Memory: Transdiagnostic Sleep and Circadian Treatment

University of California, Berkeley

NCT05986604

RECRUITING NA 120 participants

Nighttime Synchrony of Your Nutrition and Circadian Health

University of Utah

NCT07329283

RECRUITING NA 30 participants

Feasibility of Light Therapy in the Pediatric Intensive Care Unit (ICU)

Laura Beth Kalvas

NCT07384585

ACTIVE NOT RECRUITING NA 160 participants

Maintaining Behavior Change: An Evaluation of a Habit-based Sleep Health Intervention

University of California, Berkeley

NCT05167695

ACTIVE NOT RECRUITING 16 participants

Body Weight, Sleep, and Heart Health

Oregon Health and Science University

NCT03388788

ACTIVE NOT RECRUITING NA 16 participants

Circadian Health Regulation and Optimization for Rejuvenation Outcomes

Salk Institute for Biological Studies

NCT07203196

COMPLETED Phase 4 110 participants

Efficacy of Ramelteon on Insomnia Symptoms Associated With Jet Lag in Healthy Adult Volunteers

Takeda

NCT00492011

COMPLETED NA 35 participants

A Pilot Test of Mood and Circadian Rhythm Mechanisms Driving Binge Eating

University of Wyoming

NCT03680989

COMPLETED NA 20 participants

Zolpidem CR and Hospitalized Patients With Dementia

Massachusetts General Hospital

NCT00814502

COMPLETED NA 10 participants

The Impact of Artificial Sunlight on Human Sleep and Circadian Rhythms

VA Palo Alto Health Care System

NCT03636360

COMPLETED NA 10 participants

Morning Light Treatment to Improve Glucose Metabolism

Northwestern University

NCT03188263

Phase Distribution

PhaseTrial count
Phase 4 1

Named interventions

Most-linked intervention names on Circadian Dysregulation records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
2 trials
Dim Light Other
1 trials
Zolpidem CR Drug
1 trials
Natural Light Exposure Device
1 trials
Bright Light Exposure Device
1 trials
Ramelteon Drug
1 trials
Bright Light Other
1 trials
Text messaging intervention Behavioral
1 trials

US sites by state

Facility locations filed on Circadian Dysregulation trials. A trial with sites in several states counts in each.

California 4 trials
Wyoming 1 trials
Utah 1 trials
Oregon 1 trials
Ohio 1 trials
New York 1 trials
Massachusetts 1 trials
Illinois 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Circadian Dysregulation page

11 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Circadian Dysregulation condition card totals 11 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.